Marjolein P Schoonakker, Elske L van den Burg, Petra G van Peet, Saskia le Cessie, Eleanor Penny, Mattijs E Numans, Hanno Pijl, Hildo J Lamb
{"title":"A fasting-mimicking diet programme reduces abdominal adipose tissue while preserving abdominal muscle mass in persons with type 2 diabetes.","authors":"Marjolein P Schoonakker, Elske L van den Burg, Petra G van Peet, Saskia le Cessie, Eleanor Penny, Mattijs E Numans, Hanno Pijl, Hildo J Lamb","doi":"10.1016/j.numecd.2025.104111","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>This study evaluated the effects of a fasting-mimicking diet (FMD) programme alongside usual care on abdominal visceral- (aVAT) and subcutaneous (aSAT) adipose tissue, and abdominal muscle area (aMA) in persons with type 2 diabetes in primary care.</p><p><strong>Methods and results: </strong>100 persons with type 2 diabetes using metformin and/or diet alone for glycemic control were randomly assigned to receive an FMD for 5 consecutive days each month plus usual care or usual care only for 12 months. The treatment effect of the FMD on aVAT, aSAT and aMA as well as associations between changes in aVAT, aSAT or aMA, and changes in metabolic parameters were assessed. 89 participants completed baseline visits including MRI. The adjusted estimated treatment effect after 12 months in the FMD group was a loss of 37.9 cm<sup>2</sup> (95 % CI -54.7, to -21.0) in aVAT, 20.9 cm<sup>2</sup> (95 %CI -34.5 to -7.3) in aSAT and -1.6 cm<sup>2</sup> (95 % CI -4.6 to 1.4) in aMA compared to the control group. Changes in aVAT and aSAT were strongly associated with change in HbA1c and moderately with other metabolic parameters.</p><p><strong>Conclusions: </strong>A 12-month FMD programme reduced both aVAT and aSAT, while aMA remained unaffected compared to controls in persons with type 2 diabetes. The decline in aVAT and aSAT was associated with a reduction of several metabolic parameters, including HbA1c. A monthly FMD programme yields various health benefits in type 2 diabetes and appears to be a valuable treatment option as adjunct to usual care.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT03811587, 05-11-2018.</p>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":" ","pages":"104111"},"PeriodicalIF":3.3000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition Metabolism and Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.numecd.2025.104111","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aim: This study evaluated the effects of a fasting-mimicking diet (FMD) programme alongside usual care on abdominal visceral- (aVAT) and subcutaneous (aSAT) adipose tissue, and abdominal muscle area (aMA) in persons with type 2 diabetes in primary care.
Methods and results: 100 persons with type 2 diabetes using metformin and/or diet alone for glycemic control were randomly assigned to receive an FMD for 5 consecutive days each month plus usual care or usual care only for 12 months. The treatment effect of the FMD on aVAT, aSAT and aMA as well as associations between changes in aVAT, aSAT or aMA, and changes in metabolic parameters were assessed. 89 participants completed baseline visits including MRI. The adjusted estimated treatment effect after 12 months in the FMD group was a loss of 37.9 cm2 (95 % CI -54.7, to -21.0) in aVAT, 20.9 cm2 (95 %CI -34.5 to -7.3) in aSAT and -1.6 cm2 (95 % CI -4.6 to 1.4) in aMA compared to the control group. Changes in aVAT and aSAT were strongly associated with change in HbA1c and moderately with other metabolic parameters.
Conclusions: A 12-month FMD programme reduced both aVAT and aSAT, while aMA remained unaffected compared to controls in persons with type 2 diabetes. The decline in aVAT and aSAT was associated with a reduction of several metabolic parameters, including HbA1c. A monthly FMD programme yields various health benefits in type 2 diabetes and appears to be a valuable treatment option as adjunct to usual care.
背景和目的：本研究评估了模拟禁食饮食（FMD）计划和常规护理对2型糖尿病患者初级护理中腹部内脏（aVAT）和皮下（aSAT）脂肪组织和腹肌面积（aMA）的影响。方法和结果：100名单独使用二甲双胍和/或饮食控制血糖的2型糖尿病患者随机分配为每月连续5天接受FMD加常规护理或仅常规护理12个月。评估FMD对aVAT、aSAT和aMA的治疗效果，以及aVAT、aSAT或aMA变化与代谢参数变化之间的关系。89名参与者完成了包括MRI在内的基线访问。与对照组相比，FMD组12个月后调整后的估计治疗效果是aVAT减少37.9 cm2 (95% CI -54.7至-21.0)，aSAT减少20.9 cm2 (95% CI -34.5至-7.3)，aMA减少-1.6 cm2 （95% CI -4.6至1.4）。aVAT和aSAT的变化与HbA1c的变化密切相关，与其他代谢参数的变化有中等相关性。结论：与对照组相比，12个月的FMD计划降低了2型糖尿病患者的aVAT和aSAT，而aMA未受影响。aVAT和aSAT的下降与几个代谢参数的降低有关，包括HbA1c。每月一次的口蹄疫规划对2型糖尿病患者有多种健康益处，似乎是一种有价值的治疗选择，可作为常规护理的辅助手段。试验注册：ClinicalTrials.gov: NCT03811587, 05-11-2018。
期刊介绍：
Nutrition, Metabolism & Cardiovascular Diseases is a forum designed to focus on the powerful interplay between nutritional and metabolic alterations, and cardiovascular disorders. It aims to be a highly qualified tool to help refine strategies against the nutrition-related epidemics of metabolic and cardiovascular diseases. By presenting original clinical and experimental findings, it introduces readers and authors into a rapidly developing area of clinical and preventive medicine, including also vascular biology. Of particular concern are the origins, the mechanisms and the means to prevent and control diabetes, atherosclerosis, hypertension, and other nutrition-related diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
